Long-term result of endoscopic Histoacryl (N-butyl-2-cyanoacrylate) injection for treatment of gastric varices

World J Gastroenterol. 2011 Mar 21;17(11):1494-500. doi: 10.3748/wjg.v17.i11.1494.

Abstract

Aim: To evaluate the long-term efficacy and safety of endoscopic obliteration with Histoacryl(®) for treatment of gastric variceal bleeding and prophylaxis.

Methods: Between January 1994 and March 2010 at SoonChunHyang University Hospital, a total of 127 patients with gastric varices received Histoacryl(®) injections endoscopically. One hundred patients underwent endoscopic Histoacryl(®) injections because of variceal bleeding, the other 27 patients received such injections as a prophylactic procedure.

Results: According to Sarin classification, 56 patients were GOV1, 61 patients were GOV2 and 10 patients were IGV. Most of the varices were large (F2 or F3, 111 patients). The average volume of Histoacryl(®) per each session was 1.7 ± 1.3 cc and mean number of sessions was 1.3 ± 0.6. (1 session-98 patients, 2 sessions-25 patients, ≥ 3 sessions-4 patients). Twenty-seven patients with high risk of bleeding (large or fundal or RCS+ or Child C) received Histoacryl(®) injection as a primary prophylactic procedure. In these patients, hepatitis B virus was the major etiology of cirrhosis, 25 patients showed GOV1 or 2 (92.6%) and F2 or F3 accounted for 88.9% (n = 24). The rate of initial hemostasis was 98.4% and recurrent bleeding within one year occurred in 18.1% of patients. Successful hemostasis during episodes of rebleeding was achieved in 73.9% of cases. Median survival was 50 mo (95% CI 30.5-69.5). Major complications occurred in 4 patients (3.1%). The rebleeding rate in patients with hepatocellular carcinoma or GOV2 was higher than in those with other conditions. None of the 27 subjects who were treated prophylactically experienced treatment-related complications. Cumulative survival rates of the 127 patients at 6 mo, 1, 3, and 5 years were 92.1%, 84.2%, 64.2%, and 45.3%, respectively. The 6 mo cumulative survival rate of the 27 patients treated prophylactically was 75%.

Conclusion: Histoacryl(®) injection therapy is an effective treatment for gastric varices and also an effective prophylactic treatment of gastric varices which carry high risk of bleeding.

Keywords: Gastric varix; Histoacryl® (N-butyl-2-cyanoacrylate); Histoacryl® injection; Prophylaxis; Treatment of gastric varix.

MeSH terms

  • Chi-Square Distribution
  • Enbucrilate / administration & dosage*
  • Enbucrilate / adverse effects
  • Esophageal and Gastric Varices / complications
  • Esophageal and Gastric Varices / mortality
  • Esophageal and Gastric Varices / therapy*
  • Female
  • Gastrointestinal Hemorrhage / etiology
  • Gastrointestinal Hemorrhage / mortality
  • Gastrointestinal Hemorrhage / prevention & control
  • Gastrointestinal Hemorrhage / therapy*
  • Gastroscopy* / adverse effects
  • Gastroscopy* / mortality
  • Hemostasis, Endoscopic* / adverse effects
  • Hemostasis, Endoscopic* / mortality
  • Humans
  • Injections
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Recurrence
  • Republic of Korea
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Survival Rate
  • Time Factors
  • Tissue Adhesives / administration & dosage*
  • Tissue Adhesives / adverse effects
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Tissue Adhesives
  • Enbucrilate